Protective_JJ Efficacy_NN of_IN an_DT AIDS_NP Vaccine_NP ,_, a_DT Single_NP DNA_NP Priming_NP Followed_NP by_IN a_DT Single_NP Booster_NP with_IN a_DT Recombinant_NP Replication-Defective_NP Sendai_NP Virus_NP Vector_NP ,_, in_IN a_DT Macaque_NP AIDS_NP Model_NP We_PP previously_RB demonstrated_VBD the_DT excellent_JJ protective_JJ efficacy_NN of_IN DNA_NN priming_NN followed_VBN by_IN Gag-expressing_NP Sendai_NP virus_NN (_( SeV_NP )_) boosting_VBG (_( DNA_NP prime/SeV-Gag_NP boost_NN vaccine_NN )_) against_IN a_DT pathogenic_JJ simian-human_NN immunodeficiency_NN virus_NN (_( SHIV89.6PD_NP )_) infection_NN in_IN macaques_NNS ._SENT Here_RB we_PP show_VBP that_IN we_PP established_VBD a_DT practical_JJ ,_, safer_JJR AIDS_NP vaccine_NN protocol_NN ,_, a_DT single_JJ DNA_NN priming_NN followed_VBN by_IN a_DT single_JJ booster_NN with_IN a_DT recently_RB developed_VBN replication-defective_JJ F_NN deletion_NN SeV-expressing_NP Gag_NP ,_, and_CC show_VB its_PP$ protective_JJ efficacy_NN against_IN SHIV89.6PD_JJ infections_NNS ._SENT Virus-specific_JJ cellular_JJ immune_JJ responses_NNS play_VBP an_DT important_JJ role_NN in_IN the_DT control_NN of_IN immunodeficiency_NN virus_NN infections_NNS ._SENT DNA_NN vaccines_NNS ,_, recombinant-viral-vector-based_JJ vaccines_NNS ,_, and_CC their_PP$ combinations_NNS are_VBP promising_VBG AIDS_NP vaccine_NN methods_NNS because_IN of_IN their_PP$ potential_NN for_IN inducing_VBG cellular_JJ immune_JJ responses_NNS ._SENT Recently_RB ,_, some_DT of_IN these_DT AIDS_NP vaccines_NNS inducing_VBG virus-specific_JJ cellular_JJ immune_JJ responses_NNS have_VBP been_VBN reported_VBN to_TO prevent_VB AIDS_NP progression_NN in_IN macaque_NN models_NNS using_VBG pathogenic_JJ simian-human_NN immunodeficiency_NN viruses_NNS (_( SHIV_NP )_) ._SENT Members_NNS of_IN our_PP$ laboratory_NN previously_RB reported_VBD the_DT potential_NN of_IN a_DT recombinant_JJ Sendai_NP virus_NN (_( SeV_NP )_) vector_NN for_IN inducing_VBG virus-specific_JJ cellular_JJ immune_JJ responses_NNS and_CC the_DT excellent_JJ protective_JJ efficacy_NN of_IN a_DT vaccine_NN system_NN consisting_VBG of_IN DNA_NN priming_NN and_CC a_DT Gag-expressing_NP SeV_NP (_( SeV-Gag_NP )_) booster_NN in_IN a_DT macaque_NN AIDS_NP model_NN ._SENT In_IN a_DT preclinical_JJ trial_NN ,_, DNA_NP priming-SeV-Gag_NP booster_NN vaccination_NN induced_VBD high_JJ levels_NNS of_IN virus-specific_JJ T_NN cells_NNS ,_, the_DT viremia_NN in_IN all_PDT the_DT vaccinated_VBN macaques_NNS was_VBD controlled_VBN ,_, and_CC the_DT animals_NNS were_VBD protected_VBN from_IN AIDS_NP progression_NN after_IN a_DT pathogenic_JJ SHIV_NP (_( SHIV89.6PD_NP )_) challenge_NN ._SENT SeV_NP is_VBZ an_DT enveloped_VBN virus_NN with_IN a_DT negative-sense_JJ RNA_NP genome_NN ._SENT It_PP causes_VBZ fatal_JJ pneumonia_NN in_IN mice_NNS ,_, its_PP$ natural_JJ host_NN ,_, but_CC is_VBZ thought_VBN to_TO be_VB nonpathogenic_JJ in_IN primates_NNS ,_, including_VBG humans_NNS ._SENT The_DT recombinant_JJ SeV_NP vector_NN system_NN has_VBZ been_VBN shown_VBN to_TO induce_VB efficient_JJ gene_NN transfer_NN in_IN vitro_NN ._SENT A_DT recent_JJ analysis_NN confirmed_VBD that_IN SeV_NP infection_NN is_VBZ nonpathogenic_JJ in_IN macaques_NNS and_CC that_IN its_PP$ transmission_NN between_IN them_PP is_VBZ inefficient_JJ ._SENT Intranasal_NP SeV_NP inoculation_NN of_IN macaques_NNS induces_VBZ antigen_NN expression_NN localized_VBN in_IN the_DT nasal_JJ mucosa_NN and_CC its_PP$ primary_JJ lymph_NN nodes_NNS (_( LN_NP )_) ,_, the_DT submandibular_JJ LN_NP and_CC the_DT retropharyngeal_JJ LN_NP ._SENT Furthermore_RB ,_, a_DT safer_JJR replication-defective_JJ SeV_NP vector_NN lacking_VBG the_DT F_NN gene_NN ,_, F(-)SeV_NP ,_, has_VBZ recently_RB become_VBN available_JJ ._SENT The_DT DNA_NP prime/SeV-Gag_NN boost_NN regimen_NN reported_VBD previously_RB consists_VBZ of_IN a_DT series_NN of_IN four_CD vaccinations_NNS with_IN defective_JJ proviral_JJ DNA_NN and_CC a_DT single_JJ intranasal_JJ booster_NN with_IN a_DT replication-competent_JJ SeV-Gag_NP ._SENT In_IN this_DT study_NN ,_, we_PP established_VBD a_DT practical_JJ ,_, safer_JJR DNA_NN prime/SeV_NN boost_NN system_NN ,_, a_DT single_JJ DNA_NN priming_NN followed_VBN by_IN a_DT single_JJ booster_NN with_IN a_DT replication-defective_JJ F(-)SeV-expressing_NP simian_JJ immunodeficiency_NN virus_NN (_( SIV_NP )_) Gag_NP protein_NN ,_, F(-)SeV-Gag_NP ,_, for_IN clinical_JJ use_NN as_IN an_DT AIDS_NP vaccine_NN ._SENT The_DT DNA_NP priming-boosting_NN regimen_NN ,_, called_VBD DNA/F(-)SeV-Gag_NP version_NN 2_CD ,_, used_VBN in_IN this_DT study_NN consists_VBZ of_IN a_DT single_JJ DNA_NN vaccination_NN and_CC an_DT intranasal_JJ F(-)SeV-Gag_NP booster_NN at_IN week_NN 6_CD after_IN the_DT priming_NN ._SENT The_DT DNA_NN used_VBN for_IN the_DT priming_NN (_( referred_VBN to_TO as_IN CMV-SHIVdEN_NP )_) was_VBD constructed_VBN from_IN an_DT env_NN and_CC nef_NN deletion_NN SHIV_NP DNA_NP (_( SIVGP1_NP DNA_NP )_) by_IN replacing_VBG the_DT 5_CD '_POS long_JJ terminal_NN repeat_NN region_NN with_IN a_DT cytomegalovirus_NN promoter_NN with_IN an_DT immediate-early_JJ enhancer_NN and_CC the_DT 3_CD '_POS long_JJ terminal_NN repeat_NN region_NN with_IN simian_JJ virus_NN 40_CD poly(A_NN )_) ._SENT At_IN DNA_NN vaccination_NN ,_, the_DT animals_NNS received_VBD 5_CD mg_NN of_IN CMV-SHIVdEN_NP DNA_NP intramuscularly_RB ._SENT At_IN the_DT booster_NN vaccination_NN ,_, the_DT animals_NNS received_VBD 6_CD x_SYM 109_CD cell-infectious_JJ units_NNS of_IN F(-)SeV-Gag_NP intranasally_RB ._SENT All_PDT the_DT animal_JJ experiments_NNS in_IN this_DT study_NN were_VBD performed_VBN in_IN accordance_NN with_IN the_DT guidelines_NNS for_IN laboratory_NN animals_NNS of_IN the_DT National_NP Institute_NP of_IN Infectious_NP Diseases_NPS ._SENT We_PP measured_VBD virus-specific_JJ T-cell_NN levels_NNS by_IN flow-cytometric_JJ analysis_NN of_IN gamma_NN interferon_NN (_( IFN-gamma_NP )_) induction_NN after_IN specific_JJ stimulation_NN as_RB described_VBD previously_RB ._SENT In_IN brief_NN ,_, lymphocytes_NNS were_VBD cocultured_VBN with_IN autologous_JJ herpesvirus_NN papio-immortalized_VBN B_NP lymphoblastoid_JJ cell_NN lines_NNS infected_VBN with_IN a_DT recombinant_JJ vaccinia_NN virus_NN vector_NN expressing_VBG SIV_NP Gag_NP for_IN Gag-specific_NP stimulation_NN ._SENT Alternatively_RB ,_, lymphocytes_NNS were_VBD cocultured_VBN with_IN B_NP lymphoblastoid_JJ cell_NN lines_NNS infected_VBN with_IN vesicular_JJ stomatitis_NN virus_NN G-pseudotyped_NP SIVGP1_NP for_IN SHIV-specific_NP stimulation_NN ._SENT Gag-specific_JJ T-cell_NN levels_NNS and_CC SHIV-specific_JJ T-cell_NN levels_NNS were_VBD calculated_VBN by_IN subtracting_VBG IFN-gamma-positive_JJ T-cell_NN frequencies_NNS after_IN nonspecific_JJ stimulation_NN from_IN those_DT after_IN Gag-specific_NP stimulation_NN and_CC SHIV-specific_JJ stimulation_NN ,_, respectively_RB ._SENT Values_NNS exceeding_VBG 0.05_CD %_NN were_VBD considered_VBN positive_JJ ._SENT In_IN the_DT first_JJ experiment_NN ,_, we_PP examined_VBD the_DT distribution_NN of_IN the_DT F(-)SeV-Gag_NP vector_NN after_IN the_DT booster_NN ._SENT Two_CD cynomolgus_NN macaques_NNS (_( Macaca_NP fascicularis_NP )_) ,_, C97-018_NP and_CC C94-030_NP ,_, received_VBD the_DT DNA_NP prime/F(-)SeV-Gag_NN boost_NN vaccine_NN ._SENT Neither_CC of_IN them_PP showed_VBD apparent_JJ clinical_JJ symptoms_NNS ._SENT Both_CC of_IN them_PP were_VBD euthanized_JJ 2_CD weeks_NNS after_IN the_DT booster_NN ._SENT We_PP extracted_VBD RNA_NP from_IN the_DT cells_NNS prepared_VBN from_IN each_DT tissue_NN taken_VBN at_IN autopsy_NN and_CC examined_VBD F(-)SeV-Gag_NP distribution_NN by_IN detection_NN of_IN SIV_NP gag_NN after_IN nested_VBN reverse_JJ transcription-PCR_NN amplification_NN as_IN previously_RB described_VBN ._SENT The_DT vector_NN was_VBD detected_VBN in_IN the_DT nasal_JJ mucosa_NN ,_, the_DT tonsil_NN ,_, the_DT submandibular_JJ LN_NP ,_, and_CC the_DT retropharyngeal_JJ LN_NP but_CC was_VBD undetectable_JJ in_IN other_JJ lymphoid_JJ tissues_NNS ,_, including_VBG peripheral_JJ LN_NP ._SENT Reverse_JJ transcription-PCR_NN with_IN SeV_NP N-specific_NP primers_NNS showed_VBD similar_JJ results_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT These_DT results_NNS indicate_VBP that_IN F(-)SeV-Gag_NP distribution_NN was_VBD restricted_VBN to_TO the_DT nasal_JJ mucosa_NN and_CC its_PP$ primary_JJ lymphoid_JJ tissues_NNS ._SENT Flow-cytometric_JJ analysis_NN of_IN Gag-specific_NP IFN-gamma_NP induction_NN in_IN peripheral_JJ blood_NN mononuclear_JJ cells_NNS (_( PBMC_NP )_) at_IN the_DT autopsy_NN showed_VBD efficient_JJ Gag-specific_NP T-cell_NN induction_NN in_IN both_DT of_IN the_DT vaccinated_VBN macaques_NNS ._SENT Then_RB we_PP examined_VBD the_DT distribution_NN of_IN Gag-specific_NP CD8+_NP T_NN cells_NNS after_IN the_DT booster_NN ._SENT While_IN Gag-specific_NP CD8+_NP T_NN cells_NNS were_VBD detected_VBN in_IN all_PDT the_DT analyzed_VBN tissues_NNS (_( the_DT nasal_JJ mucosa_NN ,_, the_DT tonsil_NN ,_, the_DT retropharyngeal_JJ LN_NP ,_, and_CC the_DT axillary_JJ LN_NP )_) ,_, the_DT levels_NNS in_IN the_DT nasal_JJ mucosa_NN and_CC the_DT tonsil_NN harboring_VBG the_DT vector_NN were_VBD higher_JJR than_IN those_DT in_IN the_DT axillary_JJ LN_NP and_CC PBMC_NP ._SENT In_IN the_DT second_JJ experiment_NN ,_, we_PP evaluated_VBD the_DT protective_JJ efficacy_NN of_IN the_DT DNA/F(-)SeV-Gag_NP version_NN 2_CD system_NN in_IN a_DT SHIV_NP model_NN ._SENT Three_CD rhesus_NN macaques_NNS (_( Macaca_NP mulatta_NP )_) ,_, R00-020_NP ,_, R00-023_NP ,_, and_CC R00-024_NP ,_, were_VBD vaccinated_VBN for_IN the_DT challenge_NN experiment_NN ._SENT None_NN of_IN them_PP showed_VBD apparent_JJ clinical_JJ symptoms_NNS after_IN the_DT vaccination_NN ._SENT At_IN week_NN 6_CD ,_, just_RB before_IN the_DT F(-)SeV-Gag_NP booster_NN ,_, SHIV-specific_NP CD8+_NP T_NN cells_NNS were_VBD undetectable_JJ in_IN all_DT three_CD animals_NNS and_CC significant_JJ levels_NNS of_IN SHIV-specific_NP CD4+_NP T_NN cells_NNS were_VBD detected_VBN in_IN one_CD animal_NN (_( R00-023_NP )_) but_CC not_RB in_IN the_DT others_NNS ._SENT At_IN week_NN 7_CD ,_, 1_CD week_NN after_IN the_DT booster_NN ,_, all_PDT the_DT macaques_NNS showed_VBD high_JJ levels_NNS of_IN SHIV-specific_NP CD4+_NP and_CC CD8+_NP T_NN cells_NNS ,_, indicating_VBG efficient_JJ expansion_NN of_IN the_DT number_NN of_IN SHIV-specific_JJ T_NN cells_NNS as_IN a_DT result_NN of_IN the_DT F(-)SeV-Gag_NP booster_NN ._SENT The_DT levels_NNS peaked_VBN at_IN around_RB 1_CD week_NN after_IN the_DT booster_NN ._SENT Macaques_NNS R00-020_NP and_CC R00-023_NP maintained_VBD detectable_JJ levels_NNS of_IN SHIV-specific_NP CD8+_NP T_NN cells_NNS as_RB well_RB as_IN CD4+_NP T_NN cells_NNS until_IN challenge_NN at_IN week_NN 19_CD ,_, about_RB 3_CD months_NNS after_IN the_DT booster_NN ._SENT Macaque_NN R00-024_NP also_RB maintained_VBD SHIV-specific_NP CD4+_NP T_NN cells_NNS until_IN challenge_NN ,_, but_CC its_PP$ SHIV-specific_JJ CD8+-T-cell_NN level_NN declined_VBD to_TO a_DT marginal_JJ level_NN before_IN challenge_NN ._SENT These_DT three_CD macaques_NNS were_VBD intravenously_RB challenged_VBN with_IN 10_CD 50_CD %_NN tissue_NN culture_NN infective_JJ doses_NNS (_( TCID50_NP )_) of_IN SHIV89.6PD_JJ 13_CD weeks_NNS after_IN the_DT booster_NN ._SENT In_IN the_DT control_NN experiment_NN performed_VBD previously_RB ,_, all_DT four_CD naive_JJ control_NN macaques_NNS showed_VBD acute_JJ depletion_NN of_IN peripheral_JJ CD4+_NP T_NN lymphocytes_NNS 2_CD weeks_NNS after_IN the_DT challenge_NN ._SENT After_IN the_DT acute_JJ phase_NN ,_, the_DT viremia_NN in_IN three_CD of_IN the_DT macaques_NNS was_VBD not_RB controlled_VBN and_CC they_PP developed_VBD AIDS_NP and_CC were_VBD euthanized_JJ within_IN a_DT year_NN ._SENT In_IN contrast_NN ,_, all_DT three_CD macaques_NNS vaccinated_VBN with_IN the_DT DNA/F(-)SeV-Gag_NP version_NN 2_CD system_NN were_VBD protected_VBN from_IN acute_JJ AIDS_NP progression_NN ._SENT Among_IN them_PP ,_, two_CD macaques_NNS ,_, R00-020_NP and_CC R00-023_NP ,_, were_VBD protected_VBN from_IN acute_JJ CD4+-T-cell_NN depletion_NN ._SENT Their_PP$ peak_JJ viral_JJ loads_NNS in_IN plasma_NN were_VBD greatly_RB reduced_JJ (_( geometric_JJ mean_NN ,_, 5.9_CD x_SYM 105_CD copies/ml_NN )_) compared_VBN to_TO those_DT in_IN the_DT controls_NNS (_( geometric_JJ mean_NN ,_, 1.7_CD x_SYM 107_CD copies/ml_NN )_) and_CC were_VBD undetectable_JJ at_IN the_DT set_VBN point_NN ._SENT Acute_JJ viremia_NNS was_VBD not_RB controlled_VBN in_IN one_CD macaque_NN (_( R00-024_NP )_) ,_, and_CC peripheral_JJ CD4+_NP T_NN cells_NNS were_VBD lost_VBN during_IN the_DT acute_JJ phase_NN ,_, but_CC viremia_NNS was_VBD controlled_VBN and_CC CD4+_JJ T_NN cells_NNS had_VBD recovered_VBN at_IN the_DT set_VBN point_NN ._SENT We_PP then_RB examined_VBD SHIV-specific_JJ T-cell_NN levels_NNS after_IN challenge_NN ._SENT In_IN macaques_NNS R00-020_NP and_CC R00-023_NP ,_, which_WDT showed_VBD higher_JJR levels_NNS of_IN protection_NN ,_, SHIV-specific_NP CD8+_NP T_NN cells_NNS were_VBD detectable_JJ in_IN PBMC_NP even_RB at_IN week_NN 1_CD after_IN challenge_NN and_CC more_JJR vigorous_JJ secondary_JJ responses_NNS were_VBD observed_VBN after_IN that_DT ._SENT In_IN contrast_NN ,_, SHIV-specific_NP CD8+_NP T_NN cells_NNS were_VBD undetectable_JJ at_IN week_NN 1_CD in_IN macaque_NN R00-024_NP ,_, which_WDT showed_VBD a_DT lower_JJR level_NN of_IN protection_NN ,_, although_IN vigorous_JJ secondary_JJ responses_NNS were_VBD observed_VBN after_IN that_DT ._SENT These_DT results_NNS are_VBP compatible_JJ with_IN those_DT of_IN a_DT previous_JJ study_NN ,_, indicating_VBG that_IN rapid_JJ secondary_JJ responses_NNS of_IN virus-specific_JJ CD8+_NP T_NN cells_NNS are_VBP important_JJ for_IN controlling_VBG acute_JJ viremia_NN ._SENT Levels_NNS of_IN SHIV-specific_NP CD4+_NP T_NN cells_NNS were_VBD augmented_VBN in_IN all_PDT the_DT vaccinated_VBN macaques_NNS at_IN week_NN 1.5_CD after_IN challenge_NN ._SENT Both_CC of_IN the_DT macaques_NNS in_IN which_WDT acute_JJ viremia_NNS was_VBD controlled_VBN maintained_VBN these_DT levels_NNS after_IN that_DT ._SENT In_IN macaque_NN R00-024_NP ,_, SHIV-specific_NP CD4+_NP T_NN cells_NNS became_VBD undetectable_JJ at_IN week_NN 2_CD ,_, but_CC the_DT levels_NNS recovered_VBN after_IN that_DT ._SENT Thus_RB ,_, control_NN of_IN SHIV_NP infections_NNS by_IN the_DT DNA/F(-)SeV-Gag_NP vaccine_NN led_VBD to_TO maintenance_NN of_IN virus-specific_JJ CD4+_NP T_NN cells_NNS at_IN the_DT set_VBN point_NN ._SENT Recently_RB ,_, several_JJ kinds_NNS of_IN DNA_NP prime/viral_JJ vector_NN boost_NN vaccines_NNS have_VBP been_VBN shown_VBN to_TO induce_VB protective_JJ efficacy_NN against_IN pathogenic_JJ SHIV_NP infections_NNS ._SENT In_IN those_DT studies_NNS ,_, DNA_NN vaccinations_NNS were_VBD performed_VBN more_RBR than_IN once_RB ._SENT In_IN the_DT present_JJ study_NN ,_, we_PP evaluated_VBD the_DT efficacy_NN of_IN a_DT DNA_NP prime/SeV_NP boost_NN system_NN with_IN minimum_JJ numbers_NNS of_IN vaccinations_NNS in_IN an_DT SHIV_NP model_NN ._SENT Furthermore_RB ,_, this_DT study_NN is_VBZ the_DT first_JJ preclinical_JJ trial_NN of_IN a_DT replication-defective_JJ F(-)SeV_NP vector_NN as_IN a_DT vaccine_NN tool_NN ._SENT In_IN macaques_NNS ,_, the_DT vector_NN distribution_NN was_VBD localized_VBN in_IN the_DT nasal_JJ mucosa_NN ,_, its_PP$ primary_JJ LN_NP ,_, and_CC the_DT tonsil_NN after_IN an_DT intranasal_JJ F(-)SeV-Gag_NP booster_NN ._SENT The_DT distribution_NN was_VBD similar_JJ to_TO that_DT with_IN replication-competent_JJ SeV-Gag_NP ._SENT Gag-specific_NP CD8+_NP T_NN cells_NNS were_VBD detected_VBN predominantly_RB in_IN the_DT nasal_JJ mucosa_NN and_CC the_DT tonsil_NN ,_, suggesting_VBG that_IN the_DT vector-derived_JJ antigen_NN presentation_NN was_VBD predominant_JJ in_IN these_DT tissues_NNS ._SENT In_IN addition_NN to_TO the_DT local_JJ induction_NN ,_, the_DT intranasal_JJ F(-)SeV-Gag_NP injection_NN induced_VBD Gag-specific_NP CD8+_NP T_NN cells_NNS to_TO be_VB produced_VBN systemically_RB ._SENT These_DT results_NNS indicate_VBP that_IN the_DT F(-)SeV_NP vector_NN is_VBZ a_DT promising_JJ vaccine_NN tool_NN for_IN inducing_VBG virus-specific_JJ cellular_JJ immune_JJ responses_NNS ._SENT In_IN a_DT previous_JJ study_NN ,_, members_NNS of_IN our_PP$ laboratory_NN showed_VBD that_IN the_DT production_NN of_IN SHIV-specific_JJ T_NN cells_NNS was_VBD efficiently_RB induced_VBN in_IN all_DT four_CD macaques_NNS vaccinated_VBN with_IN the_DT DNA/SeV-Gag_NP version_NN 1_CD system_NN consisting_VBG of_IN a_DT series_NN of_IN four_CD DNA_NN vaccinations_NNS and_CC a_DT replication-competent_JJ SeV-Gag_NP booster_NN ._SENT All_DT of_IN them_PP maintained_VBD SHIV-specific_NP CD8+_NP T_NN cells_NNS for_IN more_JJR than_IN 3_CD months_NNS until_IN challenge_NN ,_, and_CC acute_JJ viremia_NNS was_VBD controlled_VBN without_IN acute_JJ CD4+-T-cell_NN depletion_NN after_IN SHIV89.6PD_JJ challenge_NN ._SENT Two_CD of_IN three_CD macaques_NNS vaccinated_VBN with_IN the_DT DNA/F(-)SeV-Gag_NP version_NN 2_CD system_NN in_IN this_DT study_NN showed_VBD similar_JJ levels_NNS of_IN protection_NN ;_: acute_JJ viremia_NNS was_VBD controlled_VBN without_IN acute_JJ CD4+-T-cell_NN depletion_NN ,_, and_CC they_PP were_VBD protected_VBN from_IN AIDS_NP progression_NN ._SENT On_IN the_DT other_JJ hand_NN ,_, in_IN the_DT remaining_VBG macaque_NN (_( R00-024_NP )_) with_IN a_DT marginal_JJ level_NN of_IN SHIV-specific_NP CD8+_NP T_NN cells_NNS at_IN challenge_NN ,_, acute_JJ viremia_NN was_VBD uncontrolled_JJ and_CC there_EX was_VBD acute_JJ CD4+-T-cell_NN depletion_NN ._SENT However_RB ,_, even_RB in_IN macaque_NN R00-024_NP ,_, SHIV89.6PD_NN infections_NNS were_VBD controlled_VBN at_IN the_DT set_VBN point_NN ,_, CD4+_NP T_NN cells_NNS recovered_VBD ,_, and_CC the_DT animal_NN was_VBD protected_VBN from_IN AIDS_NP progression_NN ._SENT While_IN two_CD levels_NNS of_IN protection_NN were_VBD observed_VBN ,_, this_DT study_NN indicates_VBZ that_IN even_RB the_DT DNA/F(-)SeV-Gag_NP version_NN 2_CD AIDS_NP vaccine_NN system_NN with_IN a_DT minimum_JJ number_NN of_IN vaccinations_NNS can_MD induce_VB protective_JJ immune_JJ responses_NNS in_IN a_DT macaque_NN AIDS_NP model_NN ._SENT Gag-specific_JJ CD8+-T-cell_NN levels_NNS in_IN tissues_NNS after_IN an_DT intranasal_JJ F(-)SeV-Gag_NP booster_NN ._SENT Gag-specific_JJ CD8+-T-cell_NN levels_NNS in_IN tissues_NNS after_IN an_DT intranasal_JJ F(-)SeV-Gag_NP booster_NN ._SENT Samples_NNS were_VBD obtained_VBN from_IN two_CD cynomolgus_NN macaques_NNS ,_, C97-018_NP and_CC C94-030_NP ,_, which_WDT were_VBD euthanized_JJ 2_CD weeks_NNS after_IN an_DT intranasal_JJ F(-)SeV-Gag_NP booster_NN ._SENT Numbers_NNS of_IN Gag-specific_NP CD8+_NP T_NN cells_NNS are_VBP shown_VBN as_IN percentages_NNS of_IN the_DT total_JJ number_NN of_IN CD8+_NP T_NN cells_NNS are_VBP shown_VBN as_IN percentages_NNS of_IN the_DT total_JJ number_NN of_IN CD81_JJ T_NN cells_NNS ._SENT The_DT lower_JJR panels_NNS show_VBP representative_JJ dot_NN plots_NNS of_IN IFN-g_NP induction_NN in_IN CD81_JJ T_NN cells_NNS after_IN Gag-specific_NP stimulation_NN ._SENT Dot_NN plots_NNS gated_VBN on_IN CD31_NP CD81_NP lymphocytes_NNS of_IN the_DT tonsil_NN (_( left_VBN )_) and_CC the_DT retropharyngeal_JJ LN_NP (_( right_NN )_) in_IN macaque_NN C97-018_NN are_VBP shown_VBN ._SENT Ax_NP LN_NP ,_, axillary_JJ LN_NP ;_: RP_NP LN_NP ,_, retropharyngeal_NP LN_NP ._SENT SHIV-specific-T-cell_NN levels_NNS in_IN PBMC_NP before_IN (_( A_NP )_) and_CC after_IN (_( B_NP )_) challenge_NN ._SENT SHIV-specific-T-cell_NN levels_NNS in_IN PBMC_NP before_IN (_( A_NP )_) and_CC after_IN (_( B_NP )_) challenge_NN ._SENT For_IN three_CD vaccinated_VBN rhesus_NN macaques_NNS ,_, numbers_NNS of_IN SHIV-specific_NP CD4+_NP T_NN cells_NNS (_( left_JJ panels_NNS )_) and_CC numbers_NNS of_IN SHIV-specific_NP CD8+_NP T_NN cells_NNS (_( right_JJ panels_NNS )_) are_VBP shown_VBN as_IN percentages_NNS of_IN the_DT total_JJ numbers_NNS of_IN CD4+_NP and_CC CD8+_NP T_NN cells_NNS ,_, respectively_RB ._SENT (_( A_NP )_) The_DT levels_NNS at_IN week_NN 6_CD [_SYM just_RB before_IN the_DT F(-)SeV-Gag_NP booster_NN ]_SYM ,_, week_NN 7_CD (_( 1_CD week_NN after_IN the_DT booster_NN )_) ,_, week_NN 8_CD (_( 2_CD weeks_NNS after_IN the_DT booster_NN )_) ,_, and_CC week_NN 19_CD (_( just_RB before_IN SHIV_NP challenge_NN )_) after_IN the_DT initial_JJ DNA_NN priming_NN are_VBP shown_VBN ._SENT (_( B_LS )_) The_DT levels_NNS at_IN weeks_NNS 1_CD ,_, 1.5_CD ,_, 2_CD ,_, and_CC 20_CD after_IN challenge_NN are_VBP shown_VBN ._SENT Changes_NNS in_IN peripheral_JJ CD4+-T-cell_NN counts_NNS and_CC plasma_NN viral_JJ loads_NNS after_IN SHIV89_NP ._SENT Changes_NNS in_IN peripheral_JJ CD4+-T-cell_NN counts_NNS and_CC plasma_NN viral_JJ loads_NNS after_IN SHIV89.6PD_JJ challenge_NN ._SENT The_DT left_JJ panels_NNS show_VBP results_NNS for_IN previously_RB described_VBN naive_JJ control_NN macaques_NNS (_( 17_CD )_) ,_, and_CC the_DT right_JJ panels_NNS show_VBP results_NNS for_IN macaques_NNS vaccinated_VBN with_IN the_DT DNA_NP prime/F(-)SeV-Gag_NN boost_NN vaccine_NN ._SENT (_( A_NP )_) Changes_NP in_IN relative_JJ peripheral_JJ CD4+-T-cell_NN counts_NNS (_( per_IN microliter_NN )_) ._SENT For_IN each_DT animal_NN ,_, the_DT CD4_NP count_NN at_IN the_DT challenge_NN is_VBZ considered_VBN to_TO be_VB 100_CD ,_, and_CC the_DT values_NNS for_IN the_DT CD4_NP counts_VBZ relative_JJ to_TO that_DT at_IN the_DT challenge_NN are_VBP shown_VBN ._SENT (_( B_NP )_) Changes_NP in_IN plasma_NN SHIV_NP RNA_NP copy_NN numbers_NNS (_( numbers_NNS of_IN copies_NNS per_IN milliliter_NN )_) quantified_VBN as_IN described_VBN previously_RB ._SENT Distribution_NN of_IN SIV_NP gag_NN RNA_NP 2_CD weeks_NNS after_IN a_DT F(-)SeV-Gag_NP booster_NN 